LAG3 and neoplasm: For instance, the research conducted by Long Long et al. demonstrated that combination immunotherapy involving anti-LAG-3 and anti-PD-1 exhibited remarkable efficacy against PD-1 resistance, underscoring the pivotal role played by immune checkpoint genes in tumor management47.